Patents Examined by L. Martinez
  • Compositions and methods for the treatment of carboxyhemoglobinemia
    Patent number: 10851153
    Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: December 1, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Cancer specific lipid targeted peptidomimetics
    Patent number: 10849875
    Abstract: A phosphatidylserine targeted peptoid has been identified with the ability to bind to cancer cells globally and specifically. A dimer of the peptoid decreases cancer cell viability. Use of the dimerized peptoid enhances the efficacy of docetaxel. The peptoid can be used for including but not limited to diagnosing and treating cancer, diagnosing and treating a viral condition, and diagnosing and treating diabetes.
    Type: Grant
    Filed: July 23, 2016
    Date of Patent: December 1, 2020
    Assignees: University of Houston System, Board of Regents of The University of Texas System
    Inventors: Damith Gomika Udugamasooriya, Rolf A. Brekken
  • Use of pertussis toxin as a therapeutic agent
    Patent number: 10849961
    Abstract: The present application relates to the use of pertussis toxin, and its derivatives, analogs, salts and pharmaceutical equivalents. In one embodiment, the invention provides a method of treating or preventing a neurological disease or injury by administering pertussis toxin to the individual.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: December 1, 2020
    Assignee: Dignity Health
    Inventor: Jiong Shi
  • Relaxin for treating patients afflicted of impaired glucose tolerance
    Patent number: 10842851
    Abstract: A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and/or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 24, 2020
    Assignee: Immundiagnostik AG
    Inventor: Thomas Dschietzig
  • Peptide for promoting regeneration of dentin or dental pulp tissue
    Patent number: 10844092
    Abstract: Provided are a novel peptide, a polynucleotide encoding the peptide, an expression vector including the polynucleotide, and a pharmaceutical composition including the peptide, a quasi-drug composition including the peptide, and a health functional food composition including the peptide.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: November 24, 2020
    Assignee: HysensBio Co., Ltd.
    Inventors: Joohwang Park, Jihyun Lee
  • Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
    Patent number: 10844102
    Abstract: Peptides that stimulate subcutaneous adipogenesis in mammals and uses thereof are provided.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: November 24, 2020
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Methods, agents and compositions for treatment of inflammatory conditions
    Patent number: 10821152
    Abstract: The present invention relates to the screening, diagnosis, prognostic evaluation, and treatment or prevention of age associated inflammation, chronic inflammation, and inflammatory diseases. In particular, the present invention relates to treating or preventing inflammatory diseases (e.g. rheumatoid arthritis or spondyloarthritis) or patients with inflammatory peripheral GnRH with GnRH antagonists or drugs that lower the effects of GnRH.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: November 3, 2020
    Assignee: BETANIEN HOSPITAL
    Inventor: Anita Kåss
  • Infant nutrition for improvement in insulin sensitivity later in life
    Patent number: 10821150
    Abstract: The present invention relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder appearing later in life, wherein the nutritional composition comprises casein.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: November 3, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Florence Blancher, Catherine Mace, Yassaman Shahkhalili Dulloo
  • CD31 peptides
    Patent number: 10815272
    Abstract: The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: October 27, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Compounds useful in the treatment and/or care of the skin, hair, nails, and/or mucous membranes
    Patent number: 10799442
    Abstract: Compounds of general formula (I): R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in processes of treatment and/or care of the skin, hair and/or mucous membranes, in particular in the aging and photoaging of the skin.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 13, 2020
    Assignee: LUBRIZOL ADVANCED MATERIALS, INC.
    Inventors: Nuria Alminana Domenech, Wim Van Den Nest, Maria Del Carmen Lidon, Antonio Ferrer Montiel
  • ERG targeted therapy
    Patent number: 10774122
    Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul Chinnaiyan, Xiaoju Wang
  • Composition for treating apoplexy through nasal administration
    Patent number: 10772827
    Abstract: The present invention relates to a nasal administration composition for preventing or treating ischemic cerebrovascular disease, containing a Fas targeting peptide (FTP). When using the pharmaceutical composition or kit of the present invention, a drug can be effectively delivered to brain tissue and the ischemic cerebrovascular disease of a subject can be effectively prevented or treated.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: September 15, 2020
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY
    Inventors: Sang-Kyung Lee, Irfan Ullah, Kun Ho Chung, Jung Ju Oh, Min Hyung Lee, Priti Kumar
  • Detection of platelet-derived shed CD31
    Patent number: 10775387
    Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 15, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE PARIS, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Opioid peptide
    Patent number: 10774111
    Abstract: The present invention relates to an opioid peptide represented by general formula TyrGlyGly-X1-X2-X3-X4, wherein: X1 is represented by Thr or Glu; X1 is represented by Gly or Thr or Ala; X3 is represented by Ala or Val or Gly or Glu; and X4 is represented by His or Gln or Thr or SEQ ID NO:1, or HisTyr or GlnTyr or ThrTyr. The invention also relates to pharmaceutical and food compositions comprising the peptide and to the use of the same for analgesic purposes, and/or for providing a feeling of satiety to a subject.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: September 15, 2020
    Assignees: EMBRAPA-EMPRESA BRASILEIRA DE PESQUISA AGROPECUARIA, FUNDAÇÃO UNIVERSIDADE DE BRASÍLIA—FUB—UNB
    Inventors: Carlos Bloch, Jr., Felipe Vinecky, Karla Graziella Moreira, Márcia Renata Mortari
  • Fast-off rate serum albumin binding fibronectin type III domains
    Patent number: 10766946
    Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin. Also provided are fusion molecules comprising a serum albumin binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 8, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stanley Richard Krystek, Jr., Tracy S. Mitchell, Michael L. Gosselin, Dasa Lipovsek, Juhi Juneja
  • Peptides that stimulate subcutaneous adipogenesis
    Patent number: 10766927
    Abstract: Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: September 8, 2020
    Assignee: The Regents of the University of California
    Inventors: Eva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
  • Antimicrobial peptides derived from hepatitis B virus core protein arginine-rich domain
    Patent number: 10752657
    Abstract: A pharmaceutical composition comprising: (a) an isolated peptide, wherein the peptide includes three or four arginine-rich domains (ARDs) from the carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an anti-microbial activity; and (b) a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: August 25, 2020
    Assignee: Academia Sinica
    Inventors: Chiaho Shih, Heng-Li Chen, Pei-Yi Su
  • Lipidated peptides as neuroprotective agents
    Patent number: 10751390
    Abstract: Lipidated neuropeptides PrRP31, PrRP20, containing C14 to C16 fatty acid, and their analogs, wherein a sequence of IRPVGRF-NH2 at the C-terminus is variable in the site of isoleucine, valine and phenylalanine; said fatty acid is bound in position 1 or 11 for PrRP31 or its analog and in position 1 or 7 for PrRP20 or its analog; the bond comprises an amide bond between an amino acid having at least one free NH2 group and a carboxylic group of the fatty acid and alternatively includes also a binding through arm X2, which is a hydrophilic linker selected from a group comprising ?-alanine, ?-aminobutyric acid or ?-glutamic acid; for use in the treatment and prevention of diseases, which are Alzheimer's disease (AD), Parkinson's disease (PD), cognitive impairment no dementia (CIND), brain trauma, and neurodegenerative changes and disorders.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: August 25, 2020
    Assignee: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I.
    Inventors: Lenka Maletinska, Blanka Zelezna, Miroslava Blechova, Andrea Spolcova, Barbora Mikulaskova, Jaroslav Kunes, Stepan Strnad
  • Peptides and nanoparticles for intracellular delivery of molecules
    Patent number: 10745440
    Abstract: The present invention pertains to peptides and peptide-containing complexes/nanoparticles that are useful for stabilizing and delivering cargo molecules such as nucleic acids.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: August 18, 2020
    Assignee: Aadigen, LLC
    Inventors: Gilles Divita, Neil Desai
  • Cell membrane-permeating peptide
    Patent number: 10736941
    Abstract: The present invention addresses to provide a novel membrane permeability-improving agent which can be applied to high molecular drugs. More specifically, the present invention addresses to provide: a drug carrier which can improve the absorption efficiency of a high molecular drug in the small intestine; and a membrane permeation-improving agent containing the carrier. According to the present invention, a cell membrane-permeating peptide can be provided, which comprises an amino acid sequence selected from the group consisting of the following amino acid sequences: DNPGN (SEQ ID NO: 1); SRPAF (SEQ ID NO: 2); NDPRN (SEQ ID NO: 3); and MSVAN (SEQ ID NO: 4). According to the present invention, a cell membrane-permeable composition can also be provided, which comprises the peptide and a biologically active substance.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: August 11, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Shingo Ito, Sumio Ohtsuki